decisionhealth Newsletters, Coder Pink Sheets - 2004 Issue 5 (May)
Coverage and pay increase for verteporfin
Subscribe or sign in to view the full article.
Article Overview
This article explains a Medicare coverage update affecting ocular photodynamic therapy with verteporfin and a separate payment change for the drug itself. It is relevant to ophthalmology, medical coding, and reimbursement staff who need to understand the scope of the national coverage determination, the affected clinical situations, and the associated billing context.
Why This Topic Matters
The update affects both whether certain retinal conditions may be covered under Medicare and how a related drug is reimbursed. Readers in ophthalmology and coding can use it to track policy changes tied to national coverage and payment updates.
What You Will Learn
- What Medicare updated regarding ocular photodynamic therapy coverage
- Which broad eye conditions are discussed in connection with verteporfin treatment
- What reimbursement change was announced for the drug component
- How the article frames the Medicare coverage and payment updates in billing terms
Who Should Read This
- Medical coders
- Billing staff
- Ophthalmology practices
- Reimbursement specialists
- Compliance teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com